A study to assess the safety and tolerability of AZD1390 given with radiation therapy in patients with brain cancer

Trial Identifier: D6940C00002
Sponsor: AstraZeneca
NCTID:: NCT03423628
Start Date: April 2018
Primary Completion Date: April 2026
Study Completion Date: April 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GB Cambridge, GB, CB2 0QQ
GB Glasgow, GB, G12 0YN
GB Leeds, GB, LS9 7TF
GB London, GB, W1T 7HA
US, MA Boston, MA, US, 02114
US, MA Boston, MA, US, 02215
US, NY New York, NY, US, 10065
US, PA Pittsburgh, PA, US, 15232
US, VA Richmond, VA, US, 23298